News | October 21, 2023
Laurus Labs Q2 FY24 consolidated PAT up QOQ at Rs. 36.95 Cr
Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023
Laurus Labs has reported total income of Rs. 1226.23 crores during the period ended September 30, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
This will enable the company to consume 100% of the solar energy to be supplied by Ethan Energy India Private Limited from their 10 MW Solar Energy plant
The observation is procedural in nature and the company will address the observation within stipulated timelines.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Subscribe To Our Newsletter & Stay Updated
